Bdnf Neurotrophin Signaling In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Brain-derived neurotrophic factor (BDNF) and other neurotrophins are critical signaling molecules that promote neuronal survival, differentiation, synaptic plasticity, and cognitive function. The neurotrophin family includes nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). These factors signal through Trk receptors and p75^NTR to orchestrate neuronal health. Dysregulation of neurotrophin signaling is a hallmark of Alzheimer's disease, Parkinson's disease, Huntington's disease, and other neurodegenerative disorders.
flowchart TD
A[Neurotrophins] --> B[Trk Receptors] -->
A --> C[p75NTR)
B --> D[TrkA<br>NGF] -->
B --> E[TrkB<br>BDNF/NT-4] -->
B --> F[TrkC<br>NT-3] -->
D --> G[PI3K/Akt Pathway] -->
D --> H[PLC-γ Pathway] -->
D --> I[Ras/ERK Pathway] -->
G --> J[Cell Survival] -->
H --> K[Ca²⁺ Signaling] -->
I --> L[CREB Activation] -->
J --> M[Anti-apoptotic<br>Signaling] -->
K --> N[Synaptic<br>Plasticity] -->
L --> O[Gene<br>Transcription] -->
M --> P[Neuronal<br>Survival] -->
N --> Q[Memory<br>Formation] -->
O --> P
C --> R[Pro-apoptotic<br>Signaling] -->
C --> S[Cell Death] -->
R --> S
| Neurotrophin |
Primary Receptor |
Primary Function |
Disease Relevance |
| NGF |
TrkA |
Sympathetic, sensory neurons |
AD cholinergic loss |
| BDNF |
TrkB |
CNS neurons, plasticity |
AD, PD, HD |
| NT-3 |
TrkC |
Motor neurons, CNS |
Motor neuron disease |
| NT-4 |
TrkB |
Peripheral, CNS |
Reduced in AD |
| Pathway |
Primary Kinase |
Key Effectors |
Cellular Outcome |
| PI3K/Akt |
Akt |
mTOR, Bad, GSK-3β |
Survival, growth |
| PLC-γ |
PKC |
IP3, DAG, Ca²⁺ |
Plasticity, metabolism |
| Ras/ERK |
ERK, RSK |
CREB, Elk-1 |
Differentiation, plasticity |
| Ligand Bound |
Signaling Outcome |
| Mature neurotrophins |
Pro-survival (via Trk) |
| Pro-neurotrophins |
Apoptosis (via p75^NTR) |
| No ligand |
Cell death |
| Component |
Function |
Dysfunction in Disease |
| TrkB |
Receptor tyrosine kinase |
Reduced expression in AD |
| Shc adaptor |
Recruitment |
Impaired signaling |
| PLC-γ1 |
Calcium signaling |
Synaptic deficits |
| PI3K |
Survival pathway |
Akt dysregulation |
| Ras |
ERK activation |
CREB dysfunction |
| Effector |
Target |
Function |
| Akt |
mTORC1 |
Protein synthesis |
| Akt |
Bad |
Anti-apoptosis |
| ERK |
CREB |
Transcription |
| ERK |
RSK |
Synaptic plasticity |
| PLC-γ |
PKC |
Second messengers |
- Reduced BDNF: Hippocampal expression decreases
- TrkB dysfunction: Signaling impairment
- Amyloid-β: Interferes with neurotrophin signaling
- Tau pathology: Affects axonal transport
- Cholinergic loss: NGF deficit
- BDNF: Protects dopaminergic neurons
- GDNF family: Critical for nigrostriatal pathway
- α-Synuclein: Impairs neurotrophin signaling
- Neurotrophin delivery: Therapeutic approach
- BDNF: Reduced production and transport
- Transcriptional dysregulation: CREB/cAMP defects
- TrkB signaling: Impaired
- Therapeutic potential: BDNF enhancement
- Neurotrophin support: Reduced in motor neurons
- Trk signaling: Affected by mutant proteins
- Therapeutic approaches: BDNF, CNTF trials
flowchart LR
A[TrkB Activation] --> B[PI3K/Akt] -->
B --> C[Bad Phosphorylation] -->
C --> D[Bcl-2 Activation] -->
B --> E[mTOR Activation] -->
E --> F[Protein Synthesis)
D --> G[Neuronal Survival] -->
F --> G
- LTP enhancement: BDNF-dependent
- Dendritic spine formation: Morphological changes
- Synaptic vesicle release: Enhanced neurotransmission
- Learning and memory: CREB-mediated
- Mitochondrial function: Improved energetics
- Glucose metabolism: Enhanced utilization
- Autophagy: Regulation of protein quality
| Approach |
Status |
Challenges |
| BDNF protein |
Research |
BBB penetration |
| AAV-BDNF |
Clinical trials |
Delivery, expression |
| NGF gene therapy |
Phase 3 (AD) |
Cholinergic targeting |
| GDNF delivery |
Clinical (PD) |
Brain penetration |
| Compound |
Target |
Stage |
Notes |
| 7,8-DHF |
TrkB agonist |
Research |
BDNF mimetic |
| Amitriptyline |
TrkB indirect |
Research |
Antidepressant |
| R13 |
TrkB modulator |
Research |
Neuroprotective |
| Strategy |
Mechanism |
Stage |
| Exercise |
Activity-dependent |
Proven |
| Environmental enrichment |
Behavioral |
Research |
| Dietary restriction |
Metabolic |
Research |
| HDAC inhibitors |
Epigenetic |
Research |
| Biomarker |
Source |
Significance |
| Pro-BDNF |
CSF |
Pro-apoptotic form |
| Mature BDNF |
Serum/CSF |
Active form |
| TrkB |
Tissue |
Receptor status |
| p75^NTR |
CSF |
Cell death marker |
- Selective TrkB agonists: BDNF mimetics
- Pro-drug approaches: CNS delivery
- Gene therapy vectors: Targeted expression
- Combination therapies: With other neurotrophins
| Polymorphism |
Effect |
Disease Association |
| Val66Met |
Impaired trafficking |
AD risk, PD |
| rs6265 |
Reduced BDNF |
Various |
| Various |
Altered expression |
Disease modifiers |
The study of Bdnf Neurotrophin Signaling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mattson, M.P., et al. (2008). "BDNF and amyloid-beta: a detrimental relationship in Alzheimer's disease." Journal of Neurochemistry. PMID:18363850.
- Zuccato, C., et al. (2001). "Loss of BDNF in Huntington's disease." Trends in Pharmacological Sciences. PMID:11744272.
- Huang, E.J., et al. (2001). "Neurotrophins: from neural development to neurological disease." Science. PMID:11454243.
- Chao, M.V., et al. (2006). "Neurotrophin signaling in health and disease." Clinical Science. PMID:16522145.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
4 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 31%